Article info
PDFPostScript
Correspondence
Response to: ‘Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?’ by Jones and Barry
- Correspondence to Professor J Stuart Elborn, Centre for Infection and Immunity, Queens University Belfast, Health Sciences Building, 97 Lisburn Road, Belfast BT9 7BL, UK; s.elborn{at}qub.ac.uk
Citation
Response to: ‘Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?’ by Jones and Barry
Publication history
- Received July 23, 2015
- Revised August 25, 2015
- Accepted September 29, 2015
- First published October 27, 2015.
Online issue publication
September 01, 2022
Article Versions
- Previous version (29 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/